title: The in vivo distribution of human peripheral blood lymphocytes and lymphokine-activated killer cells adoptively transferred in human pancreatic cancer-bearing nude mice.
abstract: In this study we evaluated human pancreatic cancer xenotransplanted into nude mice as a model suitable for adoptive immunotherapy studies. A pancreatic cancer cell line (MIA PaCa-2) was chosen and its growth in nude mice and sensitivity to lysis by human lymphokine-activated killer (LAK) cells were characterized. This line grew in 96% of the cases when young (4- to 6-week-old) Swiss/NIH nude mice were used. The line was highly sensitive to lysis by LAK cells in a standard chromium-51 release assay (67.8%), similarly to other cell lines known to be highly sensitive, such as K562 (75.6%) and the melanoma cell line SU.102 (53.1%). To assess their in vivo distribution, human peripheral blood lymphocytes (PBLs) and LAK cells were adoptively transferred into nude mice after labeling with indium-111 oxine. The results of this study show that adoptively transferred PBLs and LAK cells localize in this heterologous system as they do in autologous systems. PBLs are taken up mostly by the liver and spleen. The percentage of the administered dose of radioactivity taken up corrected by weight (percent dose per gram tissue) is 64.3 +/- 15.6%d/gm (liver) and 43.5 +/- 9.5%d/gm (spleen). LAK cells are taken up by liver (43.2 +/- 5.3%d/gm) and spleen (28.0 +/- 4.9%d/gm) but also localize significantly more than PBLs in other organs such as lungs (12.9 +/- 3.5%d/gm vs 1.4 +/- 0.3%d/gm, p less than 0.01), kidneys (19.1 +/- 2.1%d/gm vs 6.3 +/- 1.5%d/gm, p less than 0.001), and pancreatic tumors growing in orthotopic position (1.93 +/- 0.36%d/gm vs 0.56 +/- 0.06%d/gm, p less than 0.05). When the nude mice are pretreated with human recombinant tumor necrosis factor, localization of LAK cells compared with PBLs is even further enhanced both in tumors implanted in the pancreas (3.1 +/- 0.5%d/gm vs 0.56 +/- 0.06%d/gm, p less than 0.01) and in the subcutis (12.5 +/- 8.3%d/gm vs 0.95 +/- 0.29%d/gm, p less than 0.001).
authors.affiliation: Department of Surgery, Stanford University School of Medicine, Calif.
authors.forename: F M
authors.initials: FM
authors.lastname: Marincola
authors.forename: B J
authors.initials: BJ
authors.lastname: Drucker
authors.forename: C A
authors.initials: CA
authors.lastname: Keeling
authors.forename: D Y
authors.initials: DY
authors.lastname: Siao
authors.forename: H F
authors.initials: HF
authors.lastname: Starnes
authors.forename: D A
authors.initials: DA
authors.lastname: Goodwin
authors.forename: W D
authors.initials: WD
authors.lastname: Holder
mesh_terms: D000818:Animals; D002455:Cell Division / Q000187:drug effects; D003601:Cytotoxicity Tests, Immunologic; D006801:Humans; D007116:Immunization, Passive; D007694:Killer Cells, Natural / Q000276:immunology / Q000473:pathology / Q000637:transplantation*; D008214:Lymphocytes / Q000276:immunology* / Q000473:pathology; D008222:Lymphokines / Q000276:immunology*; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D009942:Organometallic Compounds / Q000378:metabolism / Q000494:pharmacology; D015125:Oxyquinoline / Q000031:analogs & derivatives / Q000378:metabolism / Q000494:pharmacology; D010190:Pancreatic Neoplasms / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D014183:Transplantation, Heterologous
chemical_list: D008222:Lymphokines; D009942:Organometallic Compounds; C032950:indium oxine; D015125:Oxyquinoline